Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caili Li

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Urologic Oncology|February 21, 2024
Natural history of bone-only metastasis in renal cell carcinomaBixia Tang, Rong Duan, Zenan Fan, et al.
Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insightsXuan Wang, Hui Tian, Zhihong Chi, et al.
Journal of Extracellular Vesicles|March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 TherapyLinzi Sun, Xiaoting Wei, Qian Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathwayLili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology|July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal MelanomaLirui Tang, Xiaoting Wei, Caili Li, et al.
Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy|November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trialJiayong Liu, Xuan Wang, Zhongwu Li, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Urologic Oncology|February 21, 2024
Natural history of bone-only metastasis in renal cell carcinomaBixia Tang, Rong Duan, Zenan Fan, et al.
Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insightsXuan Wang, Hui Tian, Zhihong Chi, et al.
Journal of Extracellular Vesicles|March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 TherapyLinzi Sun, Xiaoting Wei, Qian Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathwayLili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology|July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal MelanomaLirui Tang, Xiaoting Wei, Caili Li, et al.
Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy|November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trialJiayong Liu, Xuan Wang, Zhongwu Li, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Pageof 11